The 1966 U.S. Senate hearings on LSD became a public test of whether psychedelic research could be separated from the illicit market the government was determined to suppress. Timothy Leary and Sidney Cohen tried to defend the medical and scientific work, while Senator Robert F. Kennedy pressed regulators to explain why research they had accepted months earlier was now in jeopardy. The hearing exposed the widening gap between a case for controlled therapeutic use and a political effort increasingly unable to preserve that distinction.

Background: A Contested Model of Treatment

By 1966, LSD research had become difficult to contain within familiar medical categories. Earlier models treated the drug either as a temporary imitation of psychosis or as an aid to psychoanalysis. The newer psychedelic approach proposed something more disruptive: a single high-dose session aimed at a conversion experience, requiring a reimagining of the usual roles of patient and therapist. Its spiritual dimension unsettled psychiatrists seeking to establish medicine as a biochemical science, while its emphasis on the conditions surrounding a session challenged the idea that a drug’s effects could be evaluated in isolation.

The controversy also concerned who could define a legitimate use. In 1957, Sidney Cohen had resigned from Al Hubbard’s Commission for the Study of Creative Imagination, an organization whose existence signaled a growing divide between medical and spiritual approaches. Hubbard said that his regard for science as an end in itself was diminishing as he sought something beyond empirical manipulation. By the time of the hearings, the dispute had expanded from competing accounts of therapy into a struggle over whether LSD could remain within a regulated medical and research framework at all.

The Hearing: Defending Research

In May, Leary and Cohen testified before the Senate. They attempted to defend psychedelic research while drawing a line between legitimate use and the black market that officials sought to crush. Their appearance put that distinction directly before lawmakers, but the surrounding controversy made the boundary increasingly difficult to maintain.

Kennedy proved more sympathetic than the researchers might have expected. His wife, Ethel, had reportedly been treated with LSD at Hollywood Hospital in Vancouver, one of Al Hubbard’s outposts. Grilling FDA regulators about plans to cancel many of the remaining projects, Kennedy asked, “Why if [these projects] were worthwhile six months ago, why aren’t they worthwhile now?” He warned that banning psychedelics from medicine because of illicit use would be a “loss to the nation,” and argued that they could be helpful if used properly.

The Dispute Over What Counts as Evidence

The hearing’s appeal to legitimate research confronted a deeper problem: psychedelic therapy did not fit easily into the methods by which conventional medicine established a drug’s effects. Participants and guides could often tell whether a person had received psilocybin or a placebo, making blinding difficult. Researchers also could not readily separate the drug’s action from the participant’s expectations, the therapeutic relationship, or the setting in which the session took place. The very factors that could shape a therapeutic experience therefore complicated attempts to isolate a pharmacological cause.

That methodological difficulty was inseparable from the treatment’s spiritual character. Charles Grob described psychedelic therapy as a form of applied mysticism, a formulation that blurred distinctions between religion and science, sickness and health, and healer and sufferer. Critics saw such entanglements as evidence of unscientific practice; advocates argued that the treatment could not be understood by examining the chemical alone. The Senate debate took place against this unresolved conflict over the standards by which psychedelic research would be judged.

Aftermath: A Failed Appeal

Kennedy’s questions did not change the course of events. By October, roughly sixty psychedelic researchers across the United States had received an FDA letter ordering them to stop their work. At the International Foundation for Advanced Study in Menlo Park, psychologist James Fadiman remembered that the revocation arrived just as he had finished dosing four participants for a problem-solving session. He was reading the letter in the next room while the four men began their session; the program closed the following day, as did virtually every other U.S. research program then underway.

The hearing thus became a moment when the case for preserving medical research was made plainly but could not secure an institutional reprieve. Kennedy’s intervention articulated the possibility that therapeutic use and illicit use might be treated differently. The ensuing shutdown showed how little leverage that distinction retained once public controversy and regulatory action had converged.